Page 50 Guide to Pain Management in Low-Resource Settings

38 Kay Brune

References [5] Hinz B, Renner B, Brune K. Drug insight: cyclo-oxygenase-2 inhibi-
tors—a critical appraisal. Nat Clin Pract Rheumatol 2007;3:552–60.
[6] Zeilhofer HU, Brune K. Analgesic strategies beyond the inhibition of
[1] Brune K, Hinz B, Otterness I. Aspirin and acetaminophen: should they cyclooxygenases. Trends Pharmacol Sci 2006;27:467–74.
be available over the counter? Curr Rheumatol Rep 2009;11:36–40. [7] Croff ord LJ, Breyer MD, Strand CV, Rushitzka F, Brune K, Farkouh ME,
[2] Hinz B, Brune K. Can drug removals involving cyclooxygenase-2 inhibi- and Simon LS. Cardiovascular eff ects of selective COX-2 inhibition: is
tors be avoided? A plea for human pharmacology. Trends Pharmacol there a class eff ect? Th e International COX-2 Study Group. J Rheumatol
Sci 2008;8:391–7. 2006;33:1403–8.
[3] Brune K, Katus HA, Moecks J, Spanuth E, Jaff e AS, Giannitsis E. N- [8] Brune K, Hinz B. Th e discovery and development of antiinfl ammatory
terminal pro-B-type natriuretic Peptide concentrations predict the risk drugs. Arthritis Rheumatol 2004;50:2391–9.
of cardiovascular adverse events from antiinfl ammatory drugs: a pilot [9] Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and
trial. Clin Chem 2008;54:1149–57. diff erences. Scandinavian Journal of Rheumatol 2004;33:1–6.
[4] Knabl J, Witschi R, Hösl K, Reinold H, Zeilhofer UB, Ahmadi S, Brock-
haus J, Sergejeva M, Hess A, Brune K, Fritschy JM, Rudolph U, Möhler
H, Zeilhofer HU. Reversal of pathological pain through specifi c spinal
GABA receptor subtypes. Nature 2008;451:330–4.
A